About
Mark Yarchoan is an Associate Professor of Medical Oncology at Johns Hopkins with NCI-funded research in immunotherapy development, particularly cancer vaccines. He has conducted clinical trials of immunotherapy agents including neoantigen-targeted approaches.
Mark Yarchoan @markyarchoan
New work from our group @mnakazawa7 @howardli123 using the JH ICI biobank: Exceptional responders to ICIs - the “tail of the curve” - are marked by activation of the CD4/Th17 pathway https://t.co/vNYu6y7Rzm @hopkinskimmel https://t.co/stsTTODYG1
Jul 5, 2026 · ♥ 32 · ⇄ 15
Mark Yarchoan @markyarchoan
STRIDE+TACE improved PFS/OS in EMERALD-3, while durva alone did not in EMERALD-1. ➡️Pure conjecture, but a key difference: in EMERALD-3, IO was given **BEFORE** TACE - essentially neoadjuvant IO. In EMERALD-1, IO came after TACE https://t.co/VyIVbMxGTV
Jul 4, 2026 · ♥ 19 · ⇄ 13
Mark Yarchoan @markyarchoan
Faustian bargain in industry trials: Academics lend credibility and authorship, while the sponsor actually produces the the data and the analysis It is reputational outsourcing... When things go wrong, the so called “authors” are often the last to know https://t.co/TMrDoNEyg0
Jul 4, 2026 · ♥ 6 · ⇄ 1
Founder at Adventris PharmaceuticalsYC W23
Intro paths
Mark went through Y Combinator (Winter 2023) — any YC alum in your network can reach them through the YC community.
Their group partner at YC was Tom Blomfield, General Partner at Y Combinator — the partner who ran Adventris Pharmaceuticals's batch and knows the company first-hand. YC profile ↗
In turn, Mark can intro founders to Adventris Pharmaceuticals's investors below.
Adventris Pharmaceuticals's investors · 3
Co-founders at Adventris Pharmaceuticals
Founder mafias
Y Combinator mafia8,668
Also came through, then founded or led a company.
+ 8,661 more